{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:52:39Z","timestamp":1791251559133,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.anndiagpath.2026.152732","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:14Z","timestamp":1790955014000},"page":"152732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Diagnostic pitfalls in site-of-origin immunohistochemistry for metastatic carcinoma: Aberrant expression and loss of lineage-associated markers"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-472X","authenticated-orcid":false,"given":"Pravin","family":"Gadkari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Vagha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2026.152732_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00428-022-03435-z","article-title":"Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)","volume":"482","author":"Pisacane","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105821","article-title":"Updates on utility of immunohistochemistry in diagnosis of metastatic breast cancer","volume":"162","author":"Sun","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5858\/134.2.194","article-title":"Diagnosis of metastatic neoplasms: a Clinicopathologic and morphologic approach","volume":"134","author":"Marchevsky","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13000-025-01623-4","article-title":"Trichorhinophalangeal syndrome type 1 (TRPS1) in breast pathology: diagnostic utility and pitfalls","volume":"20","author":"Hashmi","year":"2025","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","article-title":"Framework for the pathology workup of metastatic castration-resistant prostate Cancer biopsies","volume":"31","author":"Haffner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.semdp.2024.05.001","article-title":"Review of immunohistochemistry techniques: applications, current status, and future perspectives","volume":"41","author":"Mebratie","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0035","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","article-title":"The transcriptional and epigenetic landscape of Cancer cell lineage plasticity","volume":"13","author":"Davies","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0040","first-page":"1063","article-title":"Cancer cell plasticity during tumor progression, metastasis and response to therapy","volume":"4","author":"P\u00e9rez-Gonz\u00e1lez","year":"2023","journal-title":"Nat Can"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67856-5","article-title":"Prostate cancer cells converge to an inflammatory-like state upon metastatic dissemination","volume":"16","author":"Keshavarzian","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","article-title":"Progressive plasticity during colorectal cancer metastasis","volume":"637","author":"Moorman","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0055","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00428-024-03872-y","article-title":"PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities","volume":"485","author":"Gorbokon","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2021.151762","article-title":"Polyclonal PAX8 expression in carcinomas of the biliary tract \u2014 frequent non-specific staining represents a potential diagnostic pitfall","volume":"53","author":"Zong","year":"2021","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0070","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/his.15358","article-title":"Evaluation of breast-specific marker expression in metastatic breast cancers: correlation with subtype switch","volume":"86","author":"Chan","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.humpath.2022.04.006","article-title":"TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma","volume":"125","author":"Yoon","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0080","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/PAS.0000000000002213","article-title":"TRPS1 is a highly sensitive marker for breast Cancer: a tissue microarray study evaluating more than 19,000 tumors from 152 different tumor entities","volume":"48","author":"Lennartz","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1309\/AJCP5UAFMSA9ZQBZ","article-title":"Immunohistochemical evaluation of GATA3 expression in tumors and Normal tissues","volume":"138","author":"Liu","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0090","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/PAS.0000000000000398","article-title":"Sox10\u2014a marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors","volume":"39","author":"Miettinen","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0095","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00428-024-03926-1","article-title":"TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities","volume":"485","author":"M\u00f6ller","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.613099","article-title":"Napsin a expression in human tumors and Normal tissues","volume":"27","author":"Weidemann","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0105","article-title":"Immunohistochemical TTF-1 and napsin a expression in gastrointestinal adenocarcinomas\u2014low frequency but an important pitfall","volume":"15","author":"Noack","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2024.105627","article-title":"The utility of the lineage specific immunohistochemical stains SATB2, CDX2, and villin, and the mucin glycoproteins MUC2, MUC5AC, and MUC6 to distinguish pulmonary invasive mucinous adenocarcinoma from metastatic colorectal carcinoma","volume":"151","author":"Rerkpichaisuth","year":"2024","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAI.0000000000001216","article-title":"Use of SATB2 and CDX2 immunohistochemistry to characterize and diagnose colorectal Cancer","volume":"32","author":"Kato","year":"2024","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0120","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/dc.23809","article-title":"Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma","volume":"45","author":"Jia","year":"2017","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.humpath.2022.10.007","article-title":"Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma","volume":"130","author":"Lin","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0130","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0135","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/dc.23075","article-title":"The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma","volume":"42","author":"Bernacki","year":"2014","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jclinpath-2014-202259","article-title":"PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?","volume":"68","author":"Barr","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.anndiagpath.2014.04.001","article-title":"Reliability of PAX8 in clinical practice to accurately determine primary site of origin in female pelvic or abdominal lesions","volume":"18","author":"Roma","year":"2014","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0150","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/his.15126","article-title":"TRPS1 is a promising marker for all subtypes of breast cancer","volume":"84","author":"Lui","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2024.152289","article-title":"Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers","volume":"71","author":"Lee","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00262-025-03964-x","article-title":"CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer","volume":"74","author":"Sirni\u00f6","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10555-023-10101-6","article-title":"Carcinoma of unknown primary (CUP): an update for histopathologists","volume":"42","author":"Beauchamp","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0175","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.5858\/arpa.2023-0483-CP","article-title":"Principles of analytic validation of Immunohistochemical assays: guideline update","volume":"148","author":"Goldsmith","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0180","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41379-020-0503-6","article-title":"Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples","volume":"33","author":"Miquelestorena-Standley","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAI.0000000000001165","article-title":"Belgian recommendations for analytical verification and validation of Immunohistochemical tests in laboratories of anatomic pathology","volume":"32","author":"Verbeke","year":"2024","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2026.105808","article-title":"Tri-layer microbiology for LMIC hospitals: linking syndromic panels with reflex culture and targeted sequencing for real world care - a narrative review","volume":"30","author":"Sahu","year":"2026","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2026.107520","article-title":"Methylation-sensitive LAMP (MS-LAMP): assay design, readouts, and clinical translation in microbiology","volume":"245","author":"Sahu","year":"2026","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/path.6022","article-title":"A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary","volume":"259","author":"Posner","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0210","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0215","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0220","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s12094-026-04241-8","article-title":"SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025)","volume":"28","author":"Losa","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0225","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0230","series-title":"occult primary (Cancer of unknown primary [CUP])","author":"National Comprehensive Cancer NetworkNetwork. NCCN cClinical pPractice gGuidelines in oOncology (NCCN gGuidelines\u00ae)","year":"2025"},{"key":"10.1016\/j.anndiagpath.2026.152732_bb0235","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913426001280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913426001280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:09:52Z","timestamp":1791248992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913426001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":47,"alternative-id":["S1092913426001280"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2026.152732","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic pitfalls in site-of-origin immunohistochemistry for metastatic carcinoma: Aberrant expression and loss of lineage-associated markers","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2026.152732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152732"}}